How to Get Rezdiffra (Resmetirom) in New York

What Is Rezdiffra and Why Does It Matter for New York Patients?

Rezdiffra (resmetirom) is the first drug approved by the FDA specifically for metabolic dysfunction-associated steatohepatitis (MASH), formerly called non-alcoholic steatohepatitis (NASH), in adults with moderate-to-advanced liver fibrosis (stages F2, F3). The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial.

New York carries a disproportionate burden of liver disease. According to the New York State Department of Health, chronic liver disease and cirrhosis rank among the top 12 causes of death statewide, and an estimated 25 to 30% of the U.S. adult population has metabolic dysfunction-associated steatotic liver disease (MASLD), the precursor to MASH [1]. For a state with over 19 million residents and large populations with obesity, type 2 diabetes, and metabolic syndrome, access to a targeted MASH therapy is a clinical priority.

Resmetirom works as a selective thyroid hormone receptor beta (THR-β) agonist. It activates hepatic THR-β to reduce liver fat, lower atherogenic lipoproteins, and decrease markers of hepatic inflammation without the cardiac side effects of systemic thyroid hormone exposure [2]. The mechanism is liver-directed. That selectivity is what separates it from older thyroid hormone analogs that were abandoned due to bone loss and tachycardia.

MAESTRO-NASH Trial Results: The Evidence Behind the Approval

In the phase 3 MAESTRO-NASH trial (N=966), resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients at 52 weeks, compared to 9.7% with placebo (P<0.001). The 100 mg dose achieved MASH resolution in 29.9% of patients versus 9.7% for placebo [1].

Fibrosis improvement of at least one stage (with no worsening of the NAFLD Activity Score) occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group, versus 14.2% for placebo [1]. These are modest absolute numbers, but they represent a meaningful shift for a disease that previously had zero approved pharmacotherapies.

Dr. Stephen Harrison, gastroenterologist and principal investigator in the MAESTRO-NASH trial, stated: "For the first time, we have a drug that directly targets the liver's metabolic dysfunction in MASH, and the biopsy-confirmed endpoints give us confidence this is real histologic improvement, not just imaging artifact."

Beyond histology, resmetirom produced significant reductions in LDL cholesterol (approximately 14 to 16% decrease), triglycerides, and liver enzymes (ALT). For New York patients with overlapping cardiovascular risk, these lipid-lowering effects carry added clinical relevance, given that cardiovascular disease, not liver failure, is the leading cause of death in MASH patients [2].

Step-by-Step: Getting a Rezdiffra Prescription in New York

The prescribing pathway requires a confirmed diagnosis, a qualified provider, and insurance navigation. Here is how each step works in New York.

Step 1: Diagnosis Confirmation. Rezdiffra's FDA label specifies use in adults with MASH and moderate-to-advanced fibrosis (F2, F3). Diagnosis typically requires one of the following: liver biopsy (the gold standard), a validated noninvasive test combination (e.g., FibroScan with a liver stiffness measurement of 8 to 14 kPa alongside elevated ALT), or MRI-based elastography. Most New York insurers accept either biopsy or FibroScan-based staging for prior authorization, though some plans still mandate biopsy [3].

Step 2: Qualified Provider Visit. Any physician (MD or DO) licensed in New York may prescribe Rezdiffra. Nurse practitioners (NPs) in New York can prescribe independently if they hold full practice authority (New York granted full practice authority to NPs effective January 2023 after a 3,600-hour transition period). Physician assistants (PAs) prescribe under a collaborative agreement with a supervising physician. Hepatologists and gastroenterologists are the most common prescribers, but endocrinologists and primary care physicians familiar with MASH may also initiate therapy.

Step 3: Baseline Lab Panel. Before prescribing, providers order: a comprehensive metabolic panel (including ALT, AST, albumin, bilirubin), FIB-4 index calculation, complete blood count, thyroid function tests (TSH, free T4), and a lipid panel. Resmetirom's THR-β agonism can suppress TSH, so baseline thyroid values are essential for monitoring [2].

Step 4: Prior Authorization Submission. The provider's office submits clinical documentation to the insurer. Required documents typically include the fibrosis staging result (biopsy pathology report or FibroScan score), baseline labs, a documented diagnosis of MASH, and confirmation that the patient does not have decompensated cirrhosis (Child-Pugh B or C). Processing takes 5 to 15 business days for most commercial plans and New York Medicaid.

Step 5: Pharmacy Fill. Once approved, the prescription is filled at a specialty pharmacy. Most fills are handled by Accredo, CVS Specialty, or Optum Specialty Pharmacy, though patients may request a New York-based specialty pharmacy.

Telehealth Access to Rezdiffra in New York

New York permits telehealth prescribing of Rezdiffra. That is straightforward.

The New York State Education Department and Department of Health allow licensed prescribers to conduct evaluations and issue prescriptions via telehealth, including for controlled and non-controlled medications. Resmetirom is not a controlled substance, which removes one common barrier [4]. A telehealth visit for Rezdiffra typically includes a video consultation, review of uploaded lab results and imaging reports, and electronic prescribing to a specialty pharmacy.

Patients in rural upstate counties, Long Island, or areas without a nearby hepatologist benefit most from telehealth access. New York has an uneven distribution of liver specialists: the majority practice in the five boroughs, Westchester, and the Albany, Capital District. Telehealth closes that gap.

One constraint: many telehealth platforms require that the prescribing provider hold an active New York medical license. Out-of-state telehealth providers may prescribe into New York only if they meet the state's temporary or full licensure requirements. Patients should verify licensure status before scheduling a telehealth hepatology visit.

The American Association for the Study of Liver Diseases (AASLD) practice guidance on MASLD supports noninvasive assessment for fibrosis staging, which aligns well with telehealth workflows where biopsy logistics are impractical [5].

New York Medicaid Coverage and Commercial Insurance

New York Medicaid covers Rezdiffra with prior authorization. The approval criteria follow the FDA label: documented MASH with fibrosis stage F2 or F3, baseline labs, and absence of decompensated cirrhosis.

For commercial plans operating in New York, coverage varies by formulary. Most major insurers (UnitedHealthcare, Anthem Blue Cross Blue Shield, Aetna, Cigna) have added Rezdiffra to specialty tiers with prior authorization requirements. Step therapy is uncommon because no other FDA-approved MASH drug exists for comparison, but some plans may require documented lifestyle intervention (diet and exercise) for 3 to 6 months before approval.

The wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year. Madrigal Pharmaceuticals offers a patient assistance program and a co-pay savings card that can reduce out-of-pocket costs for commercially insured patients to as low as $0 per month (with a maximum annual benefit cap). Patients on Medicaid or other government insurance are not eligible for the co-pay card but may qualify for the patient assistance program.

The Endocrine Society's 2024 Clinical Practice Guideline recommends pharmacotherapy for MASH patients with significant fibrosis (F2 or greater) who do not achieve adequate improvement with lifestyle modification alone, providing additional clinical support for prior authorization appeals if initially denied [6].

503A Compounding Pharmacies in New York

New York permits 503A compounding pharmacies to operate under the oversight of the New York State Board of Pharmacy. These pharmacies compound medications based on individual patient prescriptions.

A critical distinction: Rezdiffra is a brand-name product manufactured by Madrigal Pharmaceuticals, and resmetirom is not currently available as a generic. 503A pharmacies may compound resmetirom only if they can source pharmaceutical-grade active ingredient and the prescription meets the conditions for patient-specific compounding under the Federal Food, Drug, and Cosmetic Act, Section 503A. In practice, most patients will receive the commercially manufactured Rezdiffra tablet rather than a compounded formulation.

New York's Board of Pharmacy enforces strict standards for 503A facilities, including sterility testing, potency verification, and beyond-use dating. Patients should confirm that any 503A pharmacy they use holds a current New York State license and complies with USP compounding standards [7].

For patients who require dose adjustments not available in the standard 80 mg or 100 mg tablets, a 503A pharmacy could provide a compounded alternative if prescribed by a licensed provider.

Required Labs and Monitoring on Rezdiffra

Before starting Rezdiffra, New York providers order a standardized lab panel. After initiation, ongoing monitoring follows a structured schedule.

Pre-treatment labs: comprehensive metabolic panel (CMP), CBC with differential, TSH and free T4, lipid panel, FIB-4 score calculation, and hepatitis B/C serologies if not previously documented. A pregnancy test is required for women of childbearing potential, as resmetirom's effects on fetal development have not been established.

Monitoring schedule: Liver function tests (ALT, AST, bilirubin) at weeks 4, 12, and 24 after initiation, then every 6 months. TSH at week 12 and then annually. Lipid panel at week 12 and annually. The FDA label recommends discontinuation if ALT rises to greater than 5 times the upper limit of normal or if signs of hepatic decompensation develop [3].

The most common adverse effects in MAESTRO-NASH were diarrhea (26.5% vs. 17.5% placebo) and nausea (20.5% vs. 13.6% placebo) [1]. Most gastrointestinal symptoms were mild to moderate and resolved within the first 4 to 8 weeks of therapy. TSH suppression occurred in a dose-dependent manner but did not produce clinical hyperthyroidism in trial participants.

According to the AASLD guidance on MASLD and MASH, clinicians should monitor for drug-induced liver injury even with agents approved for liver disease, as baseline hepatic impairment may alter drug metabolism [5].

Transferring a Rezdiffra Prescription to New York

Patients relocating to New York or visiting from another state can transfer an active Rezdiffra prescription. New York Board of Pharmacy regulations permit prescription transfers between licensed pharmacies, including specialty pharmacies, as long as the prescription was written by a provider licensed in a U.S. state or territory.

The transfer process works as follows: the patient contacts their current specialty pharmacy, requests a transfer to a New York-licensed specialty pharmacy, and the pharmacies coordinate the transfer directly. Prior authorization may need to be re-initiated if the patient's insurance plan changes (e.g., switching from an out-of-state Medicaid plan to New York Medicaid). Prior authorizations are insurer-specific, not state-specific, so a patient keeping the same commercial insurer will typically retain their existing approval.

One practical tip: start the transfer process 2 to 3 weeks before the next refill date to avoid a gap in therapy. Interruption of resmetirom may lead to rebound liver fat accumulation, though this has not been formally studied in published trials.

Prior Authorization Documentation for New York Insurers

New York insurers require specific documentation for Rezdiffra prior authorization. Missing paperwork is the most common cause of denial or delay.

A complete prior authorization packet typically includes: the prescriber's NPI and New York license number, a letter of medical necessity, the FibroScan or liver biopsy report showing fibrosis stage F2 or F3, baseline lab values (ALT, AST, TSH, lipid panel), documentation that the patient does not have Child-Pugh B or C cirrhosis, and a statement confirming that the patient has been counseled on lifestyle modifications.

If prior authorization is denied, the patient and provider can file an appeal. New York Insurance Law Section 4904 requires insurers to provide an expedited appeal decision within 72 hours for urgent cases and 30 days for standard appeals. The New York State Department of Financial Services oversees the external review process.

Dr. Zobair Younossi, chair of the Global NASH Council and professor at Inova Medicine, has noted: "The prior authorization process for MASH therapeutics needs to reflect the urgency of progressive fibrosis. Every month of delay in treatment is a month closer to cirrhosis for patients with F3 fibrosis."

For patients denied coverage, Madrigal's bridge program may provide temporary free drug supply while appeals are processed. Contact Madrigal's patient support line at the number listed on the Rezdiffra prescribing information.

Who Should Not Take Rezdiffra

Not every MASH patient qualifies. Rezdiffra is contraindicated or not indicated in the following populations: patients with decompensated cirrhosis (Child-Pugh B or C), pregnant or breastfeeding individuals, patients with known hypersensitivity to resmetirom or any excipient, and patients with fibrosis stage F0, F1 or F4 (compensated cirrhosis is being studied in the ongoing MAESTRO-NASH-OUTCOMES trial but is not part of the current indication) [3].

Patients taking medications that strongly inhibit or induce CYP2C8 should use Rezdiffra with caution, as CYP2C8 is the primary metabolic pathway. Gemfibrozil (a strong CYP2C8 inhibitor) is specifically listed as a drug interaction requiring dose adjustment or avoidance [3].

The standard dose is 80 mg once daily for patients weighing under 100 kg, and 100 mg once daily for patients weighing 100 kg or more. Both doses are taken orally with or without food.